Amara Suebsaeng and Jessica Gilligan Named to GrowthCap's “Top Women Leaders in Growth Investing” for 2023
BOSTON, MA – TA, a leading global private equity firm, is proud to announce that Amara Suebsaeng, Director, and Jessica Gilligan, Principal, were named to GrowthCap’s annual list of “Top Women Leaders in Growth Investing” for 2023. This award honors trailblazing women in the growth investing space who have excelled due to their exceptional investment acumen, operational capabilities and work ethic.
To determine this year’s awardees, GrowthCap ran a thorough nomination process and reviewed feedback received from each nominee’s colleagues, portfolio company executives and others in the industry. Each candidate was evaluated based on her demonstrated success in her specific roles, breadth of experience, longevity in the field and consistency in performance, among other factors, including, portfolio management, firm operations and business expansion strategy.
See the full list of winners and learn more about the selection criteria and methodology on GrowthCap's Website.
About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries—technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has over 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.
This award is the opinion of the party conferring the award and not of TA. The Top Women Leaders in Growth Investing of 2023, issued by GrowthCap on 7/26/23, was based on the time period of 7/22 – 6/23. TA submitted nominations, and once selected, paid a publishing and copyright fee to promote this award. There can be no assurance that other providers or surveys would reach the same conclusion as the foregoing.